Here's one:" Lots of buzz at Dana-Farber these days about Kevetrin dose escalation.
It would appear that somebody had a look at those P21 marker levels from the first 2 cohorts ?
The PR coming next thursday has to be absolutely positive and Geoffrey Shapiro, MD is not allowed to discuss data.
My guess is that tumor regression at 3.5 grams per day and P21 biomarker will speak volumes..."

And the other - that Jeff posted a little while ago: "
There will be a huge run up to ASCO Poster presentation.
It would appear that patients in the Phase 1 Kevetrin trial at Dana Farber are responding to therapy with P53 blockbuster drug. It appears to work well on both blood and solid tissue cancers.
Soon, we will find out what large pharmaceutical is going to be our deep pocketed partner."

We has ourselves a real psychic!